Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2023 | Should we aggressively lower serum cholesterol in people with non-atherosclerotic stroke?

Hrvoje Budincevic, MD, PhD, FESO, Sveti Duh University Hospital, Zagreb, Croatia, discusses the use of lipid-lowering therapy in stroke patients with different levels of cerebral artery diseases. There is clear evidence that aggressive cholesterol-lowering improves outcomes in people with coronary artery disease and people with stroke who have evidence of atherosclerosis. Regarding the benefit of aggressive cholesterol reduction in people with cardioembolic stroke and small vessel disease, there is less certainty. But studies have shown that patients with stroke related to atrial fibrillation benefit from treatment with statins, including survival and functional outcomes. Additionally, clinicians should be aware that patients with non-atherosclerotic stroke could have subclinical atherosclerosis. This interview took place at the 17th World Congress on Controversies in Neurology (CONy) in Dubrovnik, Croatia.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Speaker’s Fees for: Bayer, Berlin Chemie Menarini, Boehringer Ingelheim, and Pfizer